Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Chemoradiotherapy in High Risk HPV-Related Oropharynx Cancer
NCT03829722Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2019
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Progression-free Survival up to 2 years. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03829722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829722.